TrkB as a therapeutic target for ovarian cancer

被引：28

作者：

Siu, Michelle K. Y. ^{[1
]}

Wong, Oscar G. W. ^{[1
]}

Cheung, Annie N. Y. ^{[1
]}

机构：

[1] Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China

来源：

EXPERT OPINION ON THERAPEUTIC TARGETS | 2009年 / 13卷 / 10期

关键词：

BDNF; ovarian cancer; therapeutic target; TrkB; NEUROTROPHIC FACTOR ACTIVATION; FOLLICLE-STIMULATING-HORMONE; TYROSINE KINASE INHIBITOR; HEPATOCYTE GROWTH-FACTOR; PROTECTS NEUROBLASTOMA-CELLS; PHASE-I TRIAL; RECEPTOR TRKB; SIGNAL-TRANSDUCTION; CEP-751; KT-6587; AUTOPHOSPHORYLATION SITES;

D O I：

10.1517/14728220903196787

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Background: In many countries, ovarian cancer is the most lethal gynecological malignancy. Its poor prognosis is mainly due to the late stage of disease with metastasis at presentation. The significant failure rate of chemotherapy in patients with advanced stage disease is also a main concern. As such, developing novel therapeutic targets is essential to improve long-term survival. Overexpression of Tropomyosin-related kinase B (TrkB), a tyrosine kinase receptor, has been documented in ovarian cancer and is found to be correlated with poor prognosis. Objective/methods: We discuss the functional roles and the related downstream signaling pathways of TrkB and its ligand brain-derived neurotrophic factor (BDNF) in ovarian cancer. The possible crosstalk between TrkB/BDNF and other putative molecular targets in ovarian cancer is also discussed. Results/conclusions: All these latest findings shed light on the application of TrkB as a therapeutic target for ovarian cancer.

引用

页码：1169 / 1178

页数：10

共 105 条

[1] Ovarian cancer: Strategies for overcoming resistance to chemotherapy [J].

Agarwal, R ;

Kaye, SB .

NATURE REVIEWS CANCER, 2003, 3 (07) :502-516

[2] Tyrosine kinase B receptor and BDNF expression in ovarian cancers - Effect on cell migration, angiogenesis and clinical outcome [J].

Au, Christy W. H. ;

Siu, Michelle K. Y. ;

Liao, Xiaoyun ;

Wong, Esther S. Y. ;

Ngan, Hextan Y. S. ;

Tam, Kar Fai ;

Chan, Dominic C. W. ;

Chan, Queeny K. Y. ;

Cheung, Annie N. Y. .

CANCER LETTERS, 2009, 281 (02) :151-161

[3] PURIFICATION OF A NEW NEUROTROPHIC FACTOR FROM MAMMALIAN BRAIN [J].

BARDE, YA ;

EDGAR, D ;

THOENEN, H .

EMBO JOURNAL, 1982, 1 (05) :549-553

[4] Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms [J].

Bonni, A ;

Brunet, A ;

West, AE ;

Datta, SR ;

Takasu, MA ;

Greenberg, ME .

SCIENCE, 1999, 286 (5443) :1358-1362

[5] Neuroblastoma: Biological insights into a clinical enigma [J].

Brodeur, GM .

NATURE REVIEWS CANCER, 2003, 3 (03) :203-216

[6] Transcription-dependent and -independent control of neuronal survival by the PI3K-Akt signaling pathway [J].

Brunet, A ;

Datta, SR ;

Greenberg, ME .

CURRENT OPINION IN NEUROBIOLOGY, 2001, 11 (03) :297-305

[7] Differential regulation of mitogen-activated protein kinases ERK1/2 and ERK5 by neurotrophins, neuronal activity, and cAMP in neurons [J].

Cavanaugh, JE ;

Ham, J ;

Hetman, M ;

Poser, S ;

Yan, C ;

Xia, ZG .

JOURNAL OF NEUROSCIENCE, 2001, 21 (02) :434-443

[8] A phase I trial of CEP-701+gemcitabine in patients with advanced adenocarcinoma of the pancreas [J].

Chan, Emily ;

Mulkerin, Daniel ;

Rothenberg, Mace ;

Holen, Kyle D. ;

Lockhart, A. Craig ;

Thomas, James ;

Berlin, Jordan .

INVESTIGATIONAL NEW DRUGS, 2008, 26 (03) :241-247

[9] Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication [J].

Chen, B ;

Dowlatshahi, D ;

MacQueen, GM ;

Wang, JF ;

Young, LT .

BIOLOGICAL PSYCHIATRY, 2001, 50 (04) :260-265

[10] VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma [J].

Chen, HZ ;

Ye, DF ;

Xie, X ;

Chen, BY ;

Lu, WG .

GYNECOLOGIC ONCOLOGY, 2004, 94 (03) :630-635

← 1 2 3 4 5 6 7 8 9 10 →